Clinical Trials
34
33 active
Approvals
13
Total approvals
Agencies
1
Regulatory bodies
Founded
N/A
Active, not recruiting
32
94.1%
Not yet recruiting
1
2.9%
Recruiting
1
2.9%
- Shionogi completed the acquisition of global rights to RADICAVA (edaravone) from Tanabe Pharma for $2.5 billion, establishing the company as a commercially viable rare disease player. - RADICAVA, approved for amyotrophic lateral sclerosis treatment, has treated over 22,000 ALS patients in the U.S. and generates approximately $700 million in annual global sales. - The acquisition includes both oral suspension and intravenous formulations of edaravone, along with an established rare disease team and ALS treatment platform. - The transaction is expected to be immediately accretive in fiscal year 2026 and supports Shionogi's 2030 Vision to address unmet medical needs in rare diseases.
- Shionogi will acquire global rights to RADICAVA (edaravone) for ALS treatment from Tanabe Pharma in a $2.5 billion transaction expected to close in Q2 2026. - The acquisition includes both oral suspension and intravenous formulations of RADICAVA, which have treated over 20,000 ALS patients in the U.S. to date. - This strategic move establishes Shionogi's commercial infrastructure in rare diseases and supports future launches of pipeline assets in Fragile X syndrome, Jordan's Syndrome, and Pompe disease. - The transaction allows Tanabe Pharma America to refocus resources on advancing promising pipeline assets while ensuring continued patient access to RADICAVA.
